Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

Completed · Phase 1

Conditions studied: Pharmacokinetics of Vepoloxamer, Healthy Volunteers, Renal Impaired

In brief

This is an open-label study designed to evaluate the effect of renal disease on the pharmacokinetics of vepoloxamer relative to the pharmacokinetics in healthy subjects with normal renal function.

Key facts

Study ID

NCT02646358

Run by

Mast Therapeutics, Inc.

People needed

27

Starts

2016-01-01

Last updated by the study team

2016-12-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• DaVita Clinical Research — Lakewood, Colorado, United States
• DaVita Clinical Research — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.